ECM
ASND icon

Endurant Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Endurant Capital Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-37,828
Closed -$1.51M – 72
2017
Q4 		$1.51M Buy
37,828
+20,498
+118% +$745K 0.46% 51
2017
Q3 		$628K Buy
+17,330
New +$497K 0.19% 76

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Endurant Capital Management's ASND Position: Q1 2018 in Review

Endurant Capital Management sold out of Ascendis Pharma A/S (ASND) in Q1 2018, closing a stake of 37,828 shares — an estimated $1.51M sold.

Endurant Capital Management first reported a position in ASND in Q3 2017 and held it in 2 quarters. The position peaked at $1.51M in Q4 2017. 92 funds tracked by Wall St. Rank hold ASND as of Q1 2018.

  • Endurant Capital Management reported no remaining Ascendis Pharma A/S position as of Q1 2018 after selling out during the quarter.
  • Endurant Capital Management sold 37,828 Ascendis Pharma A/S shares in Q1 2018, an estimated $1.51M.
  • Endurant Capital Management first reported a position in Ascendis Pharma A/S in Q3 2017 and held it in 2 quarters.
  • Endurant Capital Management's Ascendis Pharma A/S position peaked at $1.51M in Q4 2017.
  • 92 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2018.

Based on Endurant Capital Management's 13F filing for Q1 2018, filed 15 May 2018.